The ALINA trial 1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.
Keyphrases
- early stage
- advanced non small cell lung cancer
- free survival
- smoking cessation
- low dose
- computed tomography
- small cell lung cancer
- study protocol
- phase iii
- ejection fraction
- prognostic factors
- clinical trial
- sentinel lymph node
- phase ii
- newly diagnosed
- lymph node
- magnetic resonance
- blood brain barrier
- positron emission tomography
- epidermal growth factor receptor
- radiation therapy
- open label
- brain metastases
- patient reported
- image quality
- double blind